We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


TAP’s ambr™ Micro-bioreactor Mimic Shortlisted for Prestigious IChemE Award

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TAP’s ambr™ Micro-bioreactor Mimic Shortlisted for Prestigious IChemE Award"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
The Automation Partnership (TAP) announce its advanced micro-bioreactor system (ambr™) has been selected as a finalist for a prestigious Institute of Chemical Engineers (IChemE) Award, which recognizes projects for developing biotechnologies and bioprocessing applications.

TAP’s ambr system is one of four finalists competing for the bioprocessing award, which is sponsored by engineering consultancy firm, CEL International. The prize recognizes the best project to demonstrate a contribution to developing biotechnologies and bioprocessing applications and will be presented at the IChemE Annual Dinner held on 4th November 2010 at The Palace Hotel, Manchester.

Other projects shortlisted are from leading bioprocessing experts at Australia’s Monash University, as well as the UK’s University College London and Queen Mary University of London. Previous winners of the award include the Wolfson School at Loughborough University in the UK, another world leader in bioprocessing.

The ambr™ system nominated for the IChemE prize is designed using disposable micro-bioreactors controlled by an automated workstation to closely mimic the characteristics of traditional benchtop bioreactors at a 10-15 ml working volume. The system controls culture set-up and inoculation, addition of alkalis and feeds, as well as culture sampling for cell count and analysis. Its design allows users to implement completely new, faster strategies for cell line selection and process development with big reductions in costs and labour.

This technology is currently in operation at a major antibody therapeutics company, where it is being successfully used to optimize clone selection. The ambr system is also being evaluated by many companies throughout the US and Europe to determine how it can reduce time and costs of using lab scale bioreactors in process characterization.